Zafirlukast dry-powder inhalation - Invion/Hovione

Drug Profile

Zafirlukast dry-powder inhalation - Invion/Hovione

Alternative Names: INV-104

Latest Information Update: 05 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Accolade Pharmaceuticals
  • Developer Hovione; Invion
  • Class Antiallergics; Antiasthmatics; Tosyl compounds
  • Mechanism of Action Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Asthma

Most Recent Events

  • 27 Jul 2015 Early research in Asthma in Australia and Portugal (Inhalation) prior to July 2015
  • 28 Oct 2013 Accolade grants exclusive license to Invion to use zafirlukast in developing inhaled treatments for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top